Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

BACKGROUND: Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We investigated whether crizotinib could influence heart rate (HR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhushan, Huang, Tai-Qin, Nepliouev, Igor, Zhang, Hengtao, Barnett, Adam S., Rosenberg, Paul B., Ou, Sai-Hong I., Stiber, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310672/
https://www.ncbi.nlm.nih.gov/pubmed/28217366
http://dx.doi.org/10.1186/s40959-017-0020-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310672/
https://www.ncbi.nlm.nih.gov/pubmed/28217366
http://dx.doi.org/10.1186/s40959-017-0020-z

Ejemplares similares